Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.30 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3605179 | 1.00 | CYP1A2 (0.32) | CYP1A2CYP2C19L3MBTL1CYP2C9CYP2D6 | |
| SCHEMBL3605605 | 0.84 | CYP1A2 (0.38) | CYP1A2CYP2C19L3MBTL1CYP2C9CYP2D6 | |
| SCHEMBL3611386 | 0.84 | CYP1A2 (0.34) | CYP1A2CYP2C19L3MBTL1CYP2C9CYP2D6 | |
| SCHEMBL3603328 | 0.83 | PTGER4 (0.34) | CYP1A2CYP2C19L3MBTL1CYP2D6TDP1 | |
| SCHEMBL3603323 | 0.83 | PTGER4 (0.34) | CYP1A2CYP2C19L3MBTL1CYP2D6TDP1 | |
| SCHEMBL3608626 | 0.79 | L3MBTL1 (0.35) | CYP1A2CYP2C19L3MBTL1CYP2C9TDP1 | |
| SCHEMBL3605185 | 0.76 | EPHA2 (0.39) | CYP1A2CYP2C19L3MBTL1CYP2C9TDP1 | |
| SCHEMBL3600146 | 0.76 | EPHA2 (0.38) | CYP1A2CYP2C19L3MBTL1CYP2C9TDP1 | |
| SCHEMBL3603882 | 0.72 | SMN1; SMN2 (0.37) | CYP1A2CYP2C19L3MBTL1CYP2C9 | |
| SCHEMBL3603878 | 0.72 | SMN1; SMN2 (0.37) | CYP1A2CYP2C19L3MBTL1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016396-A1 | PYRAZOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128138-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016396-A1 | PYRAZOLE COMPOUND | SLC5A1, SLC5A2, GLP1R | CYP1A2 137/4885CYP2C19 79/4885L3MBTL1 3563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.